Allogene Therapeutics Announces Participation in September Investor Conference
Rhea-AI Summary
Allogene Therapeutics (Nasdaq: ALLO) announced it will participate in the Citi Biopharma Back to School Conference on Wednesday, September 9 at 5:00 a.m. PT / 8:00 a.m. ET. Any available live or replay webcasts will be accessible for about 30 days via the Investors section of the company’s website.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 12 | Q2 earnings report | Neutral | -4.3% | Clinical progress and Q2 financial results were followed by a 4.35% decline. |
| Aug 04 | Earnings date notice | Neutral | +3.3% | The company scheduled its Q2 results and business update for August 12. |
| Jul 29 | FDA designation update | Positive | +9.0% | FDA granted RMAT and Fast Track designations for cema-cel. |
| Jul 15 | Phase 1 clinical data | Positive | +2.7% | Phase 1 data showed a 25% confirmed overall response rate. |
| May 28 | CEO succession | Neutral | -3.6% | The announced CEO transition was followed by a 3.56% decline. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive clinical and regulatory announcements were followed by gains, while the Q2 results and CEO succession announcements were followed by declines.
Key Terms
allogeneic CAR T medical
chimeric antigen receptor T cell medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in the following upcoming investor conference in September.
- Citi Biopharma Back to School Conference
Wednesday, September 9
5:00 a.m. PT/8:00 a.m. ET
Any available webcasts will be posted to the Company’s website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company’s website for approximately 30 days.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of off-the-shelf CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on X (formerly Twitter) and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the heading “Risk Factors” in its most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other filings that Allogene may make from time to time with the SEC. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com
